{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T06:17:29Z","timestamp":1777184249572,"version":"3.51.4"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ygyno.2024.06.003","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T03:14:16Z","timestamp":1720062856000},"page":"147-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Ocular side effects of anticancer agents used in the treatment of gynecologic cancers"],"prefix":"10.1016","volume":"188","author":[{"given":"Fionnuala","family":"Crowley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine H.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roisin E.","family":"O'Cearbhaill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Canestraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.06.003_bb0005","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.ygyno.2024.06.003_bb0010","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.ygyno.2024.06.003_bb0015","author":"National Comprehensive Cancer Network"},{"issue":"3","key":"10.1016\/j.ygyno.2024.06.003_bb0020","first-page":"129","article-title":"Molecular targeted therapies for solid tumors: management of side effects","volume":"32","author":"Gr\u00fcnwald","year":"2009","journal-title":"Onkologie"},{"key":"10.1016\/j.ygyno.2024.06.003_bb0025","author":"Thompson"},{"issue":"36","key":"10.1016\/j.ygyno.2024.06.003_bb0030","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.06.003_bb0035","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/1759-7714.13327","article-title":"Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy","volume":"11","author":"Liu","year":"2020","journal-title":"Thoracic Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2024.06.003_bb0040","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/ICO.0000000000002934","article-title":"Refractive shifts and changes in corneal curvature associated with antibody-drug conjugates","volume":"41","author":"Canestraro","year":"2022","journal-title":"Cornea"},{"key":"10.1016\/j.ygyno.2024.06.003_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102376","article-title":"Emergence of ocular toxicities associated with novel anticancer therapeutics: what the oncologist needs to know","volume":"105","author":"Ali","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.ygyno.2024.06.003_bb0050","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2022.02.010","article-title":"Mitigation and management strategies for ocular events associated with tisotumab vedotin","volume":"165","author":"Kim","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2024.06.003_bb0055","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2024.06.003_bb0060","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.06.003_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.029","article-title":"LBA9 innovaTV 301\/ENGOT-cx12\/GOG-3057: a global, randomized, open-label, phase III study of tisotumab vedotin vs investigator\u2019s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer","volume":"34","author":"Vergote","year":"2023","journal-title":"Ann. Oncol."},{"issue":"36","key":"10.1016\/j.ygyno.2024.06.003_bb0070","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1200\/JCO.23.00720","article-title":"Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205\/GOG-3024\/ENGOT-cx8 study","volume":"41","author":"Vergote","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.06.003_bb0075","series-title":"TIVDAK TM (Tisotumab Vedotin-Tftv) Package Insert","author":"US Food and Drug Administration","year":"2024"},{"issue":"23","key":"10.1016\/j.ygyno.2024.06.003_bb0080","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"17_suppl","key":"10.1016\/j.ygyno.2024.06.003_bb0085","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5507","volume":"41","author":"Moore","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2024.06.003_bb0090","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.06.003_bb0095","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol. Ther."},{"key":"10.1016\/j.ygyno.2024.06.003_bb0100","series-title":"Package Insert for ELAHERE TM (Mirvetuximab Soravtansine-Gynx)","author":"US Food and Drug Administration","year":"2024"},{"issue":"11","key":"10.1016\/j.ygyno.2024.06.003_bb0105","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/annonc\/mdz291","article-title":"Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q","volume":"30","author":"Jhaveri","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.06.003_bb0110","author":"US Food and Drug Administration"},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.003_bb0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"17_suppl","key":"10.1016\/j.ygyno.2024.06.003_bb0120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3000","article-title":"Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results","volume":"41","author":"Meric-Bernstam","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2024.06.003_bb0125","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1200\/JCO.22.02447","article-title":"US Food and Drug Administration approval summary: fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2-low unresectable or metastatic breast cancer","volume":"41","author":"Narayan","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.ygyno.2024.06.003_bb0130","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1200\/JCO.2023.41.16_suppl.5599","article-title":"Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2","volume":"41","author":"Santin","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2024.06.003_bb0135","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.ygyno.2024.06.003_bb0140","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.003_bb0145","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","article-title":"HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now","volume":"7","author":"Schlam","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2024.06.003_bb0150","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1634\/theoncologist.2015-0149","article-title":"The therapeutic challenge of targeting HER2 in endometrial cancer","volume":"20","author":"Diver","year":"2015","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.ygyno.2024.06.003_bb0155","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40265-021-01507-z","article-title":"Ocular toxicity of targeted anticancer agents","volume":"81","author":"Fortes","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.003_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1969-3","article-title":"Trastuzumab-induced corneal ulceration: successful no-drug treatment of a \u201cblind\u201d side effect in a case report","volume":"15","author":"Orlandi","year":"2015","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2024.06.003_bb0165","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3109\/0284186X.2011.555781","article-title":"Bilateral macular ischemia and severe visual loss following trastuzumab therapy","volume":"50","author":"Saleh","year":"2011","journal-title":"Acta Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.06.003_bb0170","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ejca.2013.10.016","article-title":"Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review","volume":"50","author":"Huillard","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.06.003_bb0175","series-title":"PERJETA\u00ae (pertuzumab) Label - Accessdata.fda.gov","author":"US Food and Drug Administration","year":"2013"},{"issue":"4","key":"10.1016\/j.ygyno.2024.06.003_bb0180","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s10637-022-01256-0","article-title":"Rare ocular toxicity induced by pertuzumab\/QL1209 in healthy chinese subjects: case reports and whole-exome sequencing analysis","volume":"40","author":"Ma","year":"2022","journal-title":"Invest. New Drugs"},{"issue":"8","key":"10.1016\/j.ygyno.2024.06.003_bb0185","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-13-3077","article-title":"U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non\u2013small cell lung cancer that is anaplastic lymphoma kinase positive","volume":"20","author":"Malik","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.06.003_bb0190","author":"ALUNBRIG"},{"issue":"Suppl 2","key":"10.1016\/j.ygyno.2024.06.003_bb0195","first-page":"A1","article-title":"2022-RA-1600-ESGO Dabrafenib and trametinib for BRAF mutant low grade serous ovarian cancer","volume":"32","author":"Greenhouse","year":"2022","journal-title":"Int. J. Gynecol. Cancer."},{"issue":"7","key":"10.1016\/j.ygyno.2024.06.003_bb0200","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3390\/cancers12071823","article-title":"BRAF inhibitors: molecular targeting and immunomodulatory actions","volume":"12","author":"Proietti","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.003_bb0205","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/ERC-21-0191","article-title":"New therapeutic opportunities for women with low-grade serous ovarian cancer","volume":"29","author":"Moujaber","year":"2022","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ygyno.2024.06.003_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00221","article-title":"BRAF mutations in low-grade serous ovarian cancer and response to BRAF inhibition","volume":"2","author":"Moujaber","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ygyno.2024.06.003_bb0215","article-title":"Investigating a clinically actionable BRAF mutation for monitoring low-grade serous ovarian cancer: a case report","volume":"34","author":"Silva","year":"2022","journal-title":"Case Rep. Women\u2019s Health"},{"key":"10.1016\/j.ygyno.2024.06.003_bb0220","article-title":"Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation","volume":"40","author":"Lima","year":"2022","journal-title":"Gynecol. Oncol. Rep."},{"issue":"3","key":"10.1016\/j.ygyno.2024.06.003_bb0225","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2022.09.026","article-title":"Gynecologic tract melanoma in the contemporary therapeutic era: high rates of local and distant disease progression","volume":"167","author":"Mitra","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.06.003_bb0230","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ajo.2014.07.003","article-title":"Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib","volume":"158","author":"Choe","year":"2014","journal-title":"Am. J. Ophthalmol."},{"issue":"12","key":"10.1016\/j.ygyno.2024.06.003_bb0235","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/jamaophthalmol.2014.3024","article-title":"Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib","volume":"132","author":"Guedj","year":"2014","journal-title":"JAMA Ophthalmol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.003_bb0240","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cncr.28980","article-title":"Clinico-morphological features of BRAF inhibition\u2013induced proliferative skin lesions in cancer patients","volume":"121","author":"Belum","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.003_bb0245","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12348-023-00339-0","article-title":"Ocular side effects of trametinib and dabrafenib: a case report","volume":"13","author":"Tar\u0131m","year":"2023","journal-title":"J. Ophthalmic Inflamm. Infect."},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.003_bb0250","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12886-017-0541-0","article-title":"Ocular toxicity due to trametinib and dabrafenib","volume":"17","author":"Sarny","year":"2017","journal-title":"BMC Ophthalmol."},{"issue":"8","key":"10.1016\/j.ygyno.2024.06.003_bb0255","article-title":"Retinal vein occlusion in a patient on dabrafenib and trametinib therapy for metastatic melanoma","volume":"14","author":"Molero-Senosiain","year":"2022","journal-title":"Cureus"},{"issue":"26","key":"10.1016\/j.ygyno.2024.06.003_bb0260","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.06.003_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102225","article-title":"Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer","volume":"98","author":"Crowley","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ygyno.2024.06.003_bb0270","author":"US Food and Drug Administration"},{"key":"10.1016\/j.ygyno.2024.06.003_bb0275","article-title":"Bilateral rhegmatogenous retinal detachments in a patient taking pazopanib: a case report","volume":"26","author":"Adams","year":"2022","journal-title":"Am. J. Ophthalmol. Case Rep."},{"issue":"11","key":"10.1016\/j.ygyno.2024.06.003_bb0280","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.ophtha.2020.05.003","article-title":"Immune checkpoint inhibitor-associated optic neuritis","volume":"127","author":"Francis","year":"2020","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ygyno.2024.06.003_bb0285","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.ygyno.2024.06.003_bb0290","doi-asserted-by":"crossref","first-page":"660","DOI":"10.6004\/jnccn.2020.0027","article-title":"NCCN guidelines insights: cervical cancer, version 1.2020","volume":"18","author":"Abu-Rustum","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"2","key":"10.1016\/j.ygyno.2024.06.003_bb0295","doi-asserted-by":"crossref","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","article-title":"Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"26","key":"10.1016\/j.ygyno.2024.06.003_bb0300","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"10434","key":"10.1016\/j.ygyno.2024.06.003_bb0305","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ygyno.2024.06.003_bb0310","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.survophthal.2021.01.001","article-title":"Ocular side effects of checkpoint inhibitors","volume":"66","author":"Alba-Linero","year":"2021","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.ygyno.2024.06.003_bb0315","article-title":"Ocular adverse effects of therapeutic biologics","volume":"14","author":"Neves da Silva","year":"2022","journal-title":"Ther. Adv. Ophthalmol."},{"issue":"23","key":"10.1016\/j.ygyno.2024.06.003_bb0320","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ygyno.2024.06.003_bb0325","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ygyno.2024.06.003_bb0330","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.ophtha.2017.05.038","article-title":"Clinical and morphologic characteristics of MEK inhibitor\u2013associated retinopathy: differences from central serous chorioretinopathy","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ygyno.2024.06.003_bb0335","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000501155","article-title":"MEK inhibitor-associated central retinal vein occlusion associated with hyperhomocysteinemia and MTHFR variants","volume":"6","author":"Francis","year":"2020","journal-title":"Ocul. Oncol. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.003_bb0340","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.maturitas.2014.10.010","article-title":"Selective estrogen receptor modulators (SERMs): a review of clinical data","volume":"80","author":"Mirkin","year":"2015","journal-title":"Maturitas"},{"issue":"9","key":"10.1016\/j.ygyno.2024.06.003_bb0345","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s00432-021-03673-9","article-title":"Expression of estrogen-related receptors in ovarian cancer and impact on survival","volume":"147","author":"Schueler-Toprak","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.06.003_bb0350","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ygyno.2020.09.049","article-title":"Endocrine therapy in the management of low-grade serous ovarian\/peritoneal carcinoma: mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors","volume":"159","author":"Gershenson","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.003_bb0355","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2019.11.029","article-title":"Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma","volume":"157","author":"Fernandez","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.06.003_bb0360","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/14737140.2017.1272414","article-title":"Endocrine therapy in epithelial ovarian cancer","volume":"17","author":"Langdon","year":"2017","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"9","key":"10.1016\/j.ygyno.2024.06.003_bb0365","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.3390\/cancers12092535","article-title":"Tamoxifen and endometrial cancer: a Janus-headed drug","volume":"12","author":"Emons","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.003_bb0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2003.11.014","article-title":"What is the clinical value of adding tamoxifen to progestins in the treament of advanced or recurrent endometrial cancer?","volume":"92","author":"Herzog","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.003_bb0375","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2003.09.018","article-title":"Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a gynecologic oncology group study","volume":"92","author":"Whitney","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.06.003_bb0380","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1023\/A:1006250213357","article-title":"Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer","volume":"56","author":"Pyrh\u00f6nen","year":"1999","journal-title":"Breast Cancer Res. Treat."},{"issue":"10","key":"10.1016\/j.ygyno.2024.06.003_bb0385","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1517\/17425255.2012.708337","article-title":"Ocular toxicity from systemically administered xenobiotics","volume":"8","author":"Gokulgandhi","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.06.003_bb0390","first-page":"315","article-title":"Tamoxifen retinopathy","volume":"62","author":"Kaiser-Kupfer","year":"1978","journal-title":"Cancer Treat. Rep."},{"issue":"3","key":"10.1016\/j.ygyno.2024.06.003_bb0395","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3390\/cancers14030759","article-title":"Hormonal therapy for gynecological cancers: how far has science progressed toward clinical applications?","volume":"14","author":"Mitra","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ygyno.2024.06.003_bb0400","doi-asserted-by":"crossref","first-page":"40","DOI":"10.21873\/invivo.12674","article-title":"Ocular side effects of aromatase inhibitor endocrine therapy in breast cancer - a review","volume":"36","author":"Serban","year":"2022","journal-title":"In Vivo"},{"issue":"8","key":"10.1016\/j.ygyno.2024.06.003_bb0405","article-title":"Review of the literature on ocular complications associated with aromatase inhibitor use","volume":"13","author":"Almafreji","year":"2021","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.ygyno.2024.06.003_bb0410","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2014.02.039","article-title":"PARP inhibitors in ovarian cancer: current status and future promise","volume":"133","author":"Liu","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.06.003_bb0415","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjh.14793","article-title":"A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma","volume":"182","author":"Pratt","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.ygyno.2024.06.003_bb0420","article-title":"Potential ophthalmological side effects induced by anti-neoplastic regimens for the treatment of genitourinary cancers: a review","volume":"14","author":"Sakellakis","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.ygyno.2024.06.003_bb0425","series-title":"ZEJULA: FDA Label","author":"US Food and Drug Administration","year":"2017"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824002774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824002774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T21:23:22Z","timestamp":1738704202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824002774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":85,"alternative-id":["S0090825824002774"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.06.003","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular side effects of anticancer agents used in the treatment of gynecologic cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}